Drug Approval | November 21, 2025
Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings
Glenmark will begin distribution in November 2025
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Subscribe To Our Newsletter & Stay Updated
